Medication info
Prokin Capsule 150 milligrams (Pregabalin)

Prokin Capsule 150 milligrams (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Korea Chorus Co., Ltd.
Appearance
A hard capsule with white powder inside, white on the top and bottom.
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Active

MFDS item code 201707564 · Approved 2017.10.23 · Insurance code 647204600

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
The total daily dose of this medicine, as pregabalin, is administered orally in 2 divided doses, with or without food. Since this medicine is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be given at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be given at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be given at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg daily. The initial dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, maximum dose 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to an additional single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended. Adolescent patients aged 12-17 years: Use is not recommended.

Ingredients

Manufacturer
Korea Chorus Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia.
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults, and is used as an adjunctive treatment for partial seizures in epilepsy patients. It also helps alleviate symptoms of fibromyalgia. It is effective in improving various types of nerve-related pain and seizure symptoms.

How to take

Adult dose

The total daily dose of this medicine, as pregabalin, is administered orally in 2 divided doses, with or without food. Since this medicine is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be given at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be given at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be given at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg daily. The initial dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, maximum dose 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to an additional single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended. Adolescent patients aged 12-17 years: Use is not recommended.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, so if you experience any unusual changes in mood or behavior while taking it, you should consult your doctor immediately. You should not take this medication if you have an allergy to any of the ingredients or have specific genetic disorders. Diabetic patients may experience weight gain due to this medication, which may require adjustments in blood sugar control medications. If symptoms of allergic reactions, such as angioedema, occur, you should stop taking the medication immediately and inform your healthcare provider. Elderly patients should be careful of falls due to dizziness or drowsiness when taking this medication. This medication may cause blurred vision or changes in vision, and if symptoms persist, you should consult your doctor. Discontinuing this medication suddenly may result in withdrawal symptoms such as insomnia, headaches, and anxiety, so dosage adjustments should be made according to your doctor's instructions. Patients with a history of substance abuse should take this medication with caution due to the risk of misuse or dependence. Patients with diminished kidney function may require dosage adjustments of this medication. Patients with severe heart disease should use this medication with caution. When taken with other medications that have central nervous system depressant effects, the risk of drowsiness or respiratory depression may increase; therefore, caution is advised. During early pregnancy, there is a risk of fetal malformations, so women who are pregnant or planning to become pregnant should consult their doctor before taking this medication. Nursing mothers should discuss with their doctor whether to discontinue nursing or the medication, as this medication may pass into breast milk. Care is advised when performing activities that require concentration, such as driving or operating machinery, due to the risk of dizziness or drowsiness caused by this medication. In case of overdose, symptoms such as severe drowsiness, confusion, or seizures may occur, and you should visit a medical facility immediately for proper treatment. Keep this medication out of reach of children and do not transfer it to another container for safety.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper airway swelling
  • dizziness
  • drowsiness
Show 192 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • thoughts of suicide
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • respiratory diseases
  • neurological diseases
  • renal impairment
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual dysfunction
  • agitation
  • mood instability
  • emotional blunting
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsiveness
  • apathy
  • ataxia
  • coordination disorders
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory blunting
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • diminished reflexes
  • motor abnormalities
  • psychomotor agitation
  • orthostatic dizziness
  • hypersensitivity
  • burning sensation
  • action tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing disabilities
  • diplopia
  • vertigo
  • hyperacusis
  • first-degree AV block
  • tachycardia
  • bradycardia
  • tachyarrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distention
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasm
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling of intoxication
  • sensory disturbances
  • fatigue
  • tightness in the chest
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • malaise
  • delirium
  • paralysis (facial paralysis)
  • affective disorders
  • drowsiness
  • altered mental status
  • agitation
  • restlessness
  • exacerbation of convulsions
  • gastrointestinal disorders
  • tinnitus
  • sleep disorders
  • skin diseases
  • elevated BUN
  • hematochezia
  • shock
  • anaphylactic-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is best to store it at room temperature between 15 degrees and 30 degrees.

Appearance and packaging

Appearance

A hard capsule with white powder inside, white on the top and bottom.

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.